Cargando…
Recovery of proteasome activity in cells pulse-treated with proteasome inhibitors is independent of DDI2
Rapid recovery of proteasome activity may contribute to intrinsic and acquired resistance to FDA-approved proteasome inhibitors. Previous studies have demonstrated that the expression of proteasome genes in cells treated with sub-lethal concentrations of proteasome inhibitors is upregulated by the t...
Autores principales: | Ibtisam, Ibtisam, Kisselev, Alexei F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10418215/ https://www.ncbi.nlm.nih.gov/pubmed/37577495 http://dx.doi.org/10.1101/2023.08.03.550647 |
Ejemplares similares
-
Site-Specific Proteasome Inhibitors
por: Kisselev, Alexei F.
Publicado: (2021) -
The aspartyl protease DDI2 activates Nrf1 to compensate for proteasome dysfunction
por: Koizumi, Shun, et al.
Publicado: (2016) -
Disabling the Protease DDI2 Attenuates the Transcriptional Activity of NRF1 and Potentiates Proteasome Inhibitor Cytotoxicity
por: Northrop, Amy, et al.
Publicado: (2020) -
The aspartyl protease DDI2 drives adaptation to proteasome inhibition in multiple myeloma
por: Op, Mélanie, et al.
Publicado: (2022) -
A clinically relevant pulse treatment generates a bortezomib-resistant myeloma cell line that lacks proteasome mutations and is sensitive to Bcl-2 inhibitor venetoclax
por: Downey-Kopyscinski, Sondra L., et al.
Publicado: (2022)